CRI
Carter's, Inc.
CRI has the edge over NIO overall, supported by stronger valuation and lower modeled downside.
NIO
NIO Inc.
NIO offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
CRI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
CRI's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NIO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Stable | |
| Unavailable |
NIO's revenue is currently strong, and its profitability and cash flow are stable. There isn't enough data to rate its balance sheet.
CRI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 5.6x | $33.87 | — |
| Cheap | 8.6x | $51.89 | +53% |
| Forward | 10x | $33.87 | — |
| Fair | 12x | $74.79 | +121% |
| Expensive | 18x | $107 | +215% |
Historical ranges are pointers, not guarantees.
CRI's PE is in its cheap range at 5.6x. On analysts' estimates for next year's earnings, today's price would be 10x.
NIO PE Valuation
NIO has no meaningful PE right now: it lost money over the past year.
CRI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect CRI's earnings to grow and its profitability to improve, with its revenue holding steady.
NIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
NIO has the edge over CRI on the outlook, with more favorable revenue expectations.
CRI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.24 | -46% |
| Q3 2026 | $6.03 | +145% |
| Q2 2026 | $5.35 | +42% |
| Q1 2026 | $2.49 | -45% |
| Q4 2025 | $2.53 | -51% |
| Q3 2025 | $2.46 | -61% |
| Q2 2025 | $3.76 | -42% |
| Q1 2025 | $4.51 | -29% |
| Q4 2024 | $5.12 | -18% |
CRI has the edge over NIO on earnings quality, reporting a profit while its opponent remains loss making.
NIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.29 | +$1.45 |
| Q1 2026 | -$0.60 | +$1.16 |
| Q4 2025 | -$1.06 | +$0.60 |
| Q3 2025 | -$1.59 | +$0.02 |
| Q2 2025 | -$1.74 | -$0.10 |
| Q1 2025 | -$1.76 | +$0.06 |
| Q4 2024 | -$1.66 | +$0.21 |
| Q3 2024 | -$1.61 | +$0.32 |
NIO is still losing money, but far less than before: $0.29 per share over the past year, against $1.93 at its worst in late 2023.
CRI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $752.5M | -0.7% |
| Q2 2026 | $615.5M | +5.2% |
| Q1 2026 | $681.1M | +8.1% |
| Q4 2025 | $925.5M | +7.6% |
| Q3 2025 | $757.8M | -0.1% |
| Q2 2025 | $585.3M | +3.7% |
| Q1 2025 | $629.8M | -4.8% |
| Q4 2024 | $859.7M | +0.2% |
CRI's revenue has picked up after two years of holding roughly level: $752M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.4% | +3.6 points |
| Q2 2026 | 23% | +22 points |
| Q1 2026 | 4.2% | 0 points |
| Q4 2025 | 9.2% | -0.5 points |
| Q3 2025 | 3.8% | -6.3 points |
| Q2 2025 | 0.7% | -6.3 points |
| Q1 2025 | 4.1% | -4.2 points |
| Q4 2024 | 9.7% | -6.2 points |
CRI has the edge over NIO on profitability, with a higher operating margin.
NIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.8B | +69% |
| Q1 2026 | $3.8B | +112% |
| Q4 2025 | $5.2B | +76% |
| Q3 2025 | $3.3B | +17% |
| Q2 2025 | $2.9B | +9% |
| Q1 2025 | $1.8B | +21% |
| Q4 2024 | $3B | +15% |
| Q3 2024 | $2.8B | -2.1% |
NIO has the edge over CRI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2.1% | +24 points |
| Q1 2026 | -1.2% | +52 points |
| Q4 2025 | 2.3% | +33 points |
| Q3 2025 | -16% | +12 points |
| Q2 2025 | -26% | +4 points |
| Q1 2025 | -53% | +1.1 points |
| Q4 2024 | -31% | +8.1 points |
| Q3 2024 | -28% | -2.6 points |
NIO's operating margin was −2.1% last quarter, up 24 points from the same quarter a year ago.
CRI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$117.4M | +$26.7M |
| Q2 2026 | $190M | +688% |
| Q1 2026 | -$543K | +$58.4M |
| Q4 2025 | $247.6M | -8.6% |
| Q3 2025 | -$144.1M | -$48.4M |
| Q2 2025 | $24.1M | -77% |
| Q1 2025 | -$59M | -$21.4M |
| Q4 2024 | $270.9M | -11% |
CRI usually generates cash, though not every quarter: the latest was −$117M, but it generated $320M over the past year.
NIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | +$2.1B |
| Q1 2026 | $0 | $0 |
| Q4 2025 | $0 | +$391.3M |
| Q3 2025 | $0 | $0 |
| Q2 2025 | -$2.1B | +$73.9M |
| Q1 2025 | $0 | $0 |
| Q4 2024 | -$391.3M | -386% |
| Q2 2024 | -$2.2B | +$337.9M |
NIO has the edge over CRI on cash flow, with more consistent year-over-year improvement.
CRI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +36.1K shares |
| 1 year | +0.5% | +192K shares |
| 3 years | -2.2% | -806K shares |
| 5 years | -18% | -7.8M shares |
| Available history | -20% | -9.1M shares |
CRI has the edge over NIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $16.7M |
| Q2 2024 | $24.8M |
| Q1 2024 | $9M |
NIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +15.6M shares |
| 1 year | +12% | +267M shares |
| 3 years | +51% | +844M shares |
| 5 years | +60% | +933M shares |
| Available history | +143% | +1.5B shares |
NIO has 2.5B diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NIO hasn't bought back shares in the past year.
CRI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.3x | Very low |
CRI's net debt is less than a year of its operating earnings (EBITDA), down from 1.6 years a year ago.
NIO Net Leverage
NIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CRI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 29.2 | Neutral |
CRI's weekly RSI is 49 (neutral) and its Stochastic is 29 (neutral).
NIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 6.9 | Oversold |
NIO's weekly RSI is 31 (neutral) and its Stochastic is 7 (oversold).
CRI PE vs Consumer Cyclical Sector
| Metric | CRI | Sector median | Relative |
|---|---|---|---|
| PE | 5.6x | 18x | 69% below |
| PE % | 1 | 47 | 46 pts below |
CRI is trading at 5.6x earnings, a 69% discount to the Consumer Cyclical sector's median of 18x.
NIO PE vs Consumer Cyclical Sector
NIO has no meaningful PE right now: it lost money over the past year.
CRI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $32.1 | 5.5% above |
| 20 week MA | $34.7 | 2.5% below |
| 50 week MA | $35.7 | 5% below |
| 100 week MA | $36.0 | 6% below |
| 200 week MA | $52.7 | 36% below |
CRI has the edge over NIO on trend strength, trading above more of its moving averages.
NIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.36 | 9.2% below |
| 20 week MA | $4.01 | 24% below |
| 50 week MA | $4.81 | 37% below |
| 100 week MA | $4.85 | 37% below |
| 200 week MA | $6.03 | 49% below |
NIO is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
CRI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $110.1 | $95.0 | -14% |
| 2021 | $95.0 | $98.7 | +3.9% |
| 2022 | $98.7 | $73.4 | -26% |
| 2023 | $73.4 | $74.9 | +2.1% |
| 2024 | $74.9 | $54.4 | -27% |
| 2025 | $54.4 | $31.7 | -42% |
| 2026 YTD | $31.7 | $33.9 | +6.9% |
CRI has the edge over NIO on returns for 2026, with the stronger performance.
NIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.42 | $45.8 | +1791% |
| 2021 | $45.8 | $30.5 | -33% |
| 2022 | $30.5 | $11.0 | -64% |
| 2023 | $11.0 | $9.07 | -17% |
| 2024 | $9.07 | $4.48 | -51% |
| 2025 | $4.48 | $5.10 | +14% |
| 2026 YTD | $5.10 | $3.05 | -40% |
NIO's yearly returns have swung widely, from +1791% in 2020 to −64% in 2022. It's down 40% so far in 2026.